Alendronate Sodium Tablets
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Logistics Agency (DLA) Troop Support has awarded Exelan Pharmaceuticals, Inc. a contract (SPE2D2-26-D-0009) for the supply of Alendronate Sodium Tablets. This award, resulting from solicitation SPE2D2-25-R-0023, has an estimated total value of $4,457,450.00 over a five-year period. The award effective date was June 8, 2026.
Scope of Work
The contract covers the provision of Alendronate Sodium tablets in two dosages:
- 35MG tablets (4 Count per box)
- 70MG tablets (4 Count per box) The place of performance is Piscataway, NJ, United States.
Contract & Timeline
- Contract Number: SPE2D2-26-D-0009
- Solicitation Number: SPE2D2-25-R-0023
- Awarded To: Exelan Pharmaceuticals, Inc.
- Total Award Value: $4,457,450.00
- Period of Performance: 5 years
- Award Effective Date: June 8, 2026
- Set-Aside: Not specified
- Product Service Code: 6505 (Drugs And Biologicals)
Evaluation
The award was based on Exelan Pharmaceuticals, Inc.'s Final Proposal Revision, which was determined to be the Lowest Price Technically Acceptable (LPTA).
Additional Notes
The award document incorporates by reference the original solicitation, Amendment 0001, and Exelan Pharmaceuticals, Inc.'s Business Subcontracting Plan. The original solicitation was issued on September 23, 2025, with an offer due date of November 3, 2025 (extended from October 27, 2025).